KDAC VARIANTS AND USES THEREOF
The present invention relates to a mutant polypeptide comprising an amino acid sequence having at least 98% sequence homology with SEQ ID NOs: 4, 5, 6, 7 or 8 and having lysine demodification activity, wherein the mutant polypeptide is not identical to SEQ ID NO: 1. The invention also relates to the...
Saved in:
Main Authors | , |
---|---|
Format | Patent |
Language | English French German |
Published |
27.03.2019
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | The present invention relates to a mutant polypeptide comprising an amino acid sequence having at least 98% sequence homology with SEQ ID NOs: 4, 5, 6, 7 or 8 and having lysine demodification activity, wherein the mutant polypeptide is not identical to SEQ ID NO: 1. The invention also relates to the mutant polypeptide of the invention and a peptide or polypeptide comprising an inactivated essential lysine residue for use in treating cancer. The invention furthermore provides for a method of screening for a mutant polypeptide having lysine demodification activity, wherein the method comprises the following steps (a) incubating a mutant polypeptide having an amino acid sequence with at least 80% sequence identity to SEQ ID NO: 1 with a peptide or polypeptide comprising an inactivated essential lysine residue; and (b) determining the activity of the mutant polypeptide to activate the peptide or polypeptide comprising the inactivated essential lysine residue, wherein the mutant polypeptide and the peptide or polypeptide comprising an inactivated essential lysine residue are incubated in a biological cell. |
---|---|
Bibliography: | Application Number: EP20170192670 |